Oral drug delivery system
Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.
1. An oral formulation comprising:
oxycodone;
sucrose acetate isobutyrate (SAIB);
a cellulose acetate butyrate (CAB) having a number average molecular weight ranging from 66,000 Daltons to 83,000 Daltons;
isopropyl myristate (IPM); and
a solvent selected from the group consisting of triacetin and ethyl lactate (EL).
2. The oral formulation of claim 1 , wherein the solvent is triacetin.
3. The oral formulation of claim 1 , wherein the CAB has a butyryl content ranging from about 17% to about 38%.
4. The oral formulation of claim 1 , wherein the CAB has an acetyl content ranging from about 13% to about 30%.
5. The oral formulation of claim 1 , wherein the CAB has a hydroxyl content ranging from about 0.8% to about 1.7%.
6. The oral formulation of claim 1 , wherein the CAB has a butyryl content ranging from about 17% to about 38%, an acetyl content ranging from about 13% to about 30%, and a hydroxyl content ranging from about 0.8% to about 1.7%.
7. The oral formulation of claim 1 , wherein the formulation comprises from about 1 to about 8.6 weight percent of the CAB.
8. The oral formulation of claim 1 , wherein the formulation comprises from about 20 to about 50 weight percent of the solvent.
9. The oral formulation of claim 1 , wherein the formulation comprises from about 1 to about 75 weight percent IPM.
10. An oral dosage form comprising the formulation of claim 1 , wherein the formulation is contained in a capsule.
11. The oral dosage form of claim 10 , wherein the capsule comprises gelatin or hydroxyl propylmethyl cellulose.
12. The oral dosage form of claim 10 , wherein the capsule is a hard capsule comprising gelatin or hydroxyl propylmethyl cellulose.
13. The oral formulation of claim 1 , wherein the formulation comprises:
from about 1 to about 8.6 weight percent of the CAB;
from about 20 to about 50 weight percent of the solvent; and
from about 1 to about 75 weight percent IPM.
14. The oral formulation of claim 13 , wherein the formulation comprises from 3 to 7.8 weight percent of the CAB.
15. The oral formulation of claim 14 , wherein the CAB has a butyryl content ranging from about 17% to about 38%.
16. The oral formulation of claim 14 , wherein the CAB has an acetyl content ranging from about 13% to about 30%.
17. The oral formulation of claim 14 , wherein the CAB has a hydroxyl content ranging from about 0.8% to about 1.7%.
18. The oral formulation of claim 14 , wherein the CAB has a butyryl content ranging from about 17% to about 38%, an acetyl content ranging from about 13% to about 30%, and a hydroxyl content ranging from about 0.8% to about 1.7%.
19. An oral dosage form comprising the formulation of claim 14 , wherein the formulation is contained in a capsule.
20. The oral dosage form of claim 19 , wherein the capsule comprises gelatin or hydroxyl propylmethyl cellulose.
21. The oral dosage form of claim 19 , wherein the capsule is a hard capsule comprising gelatin or hydroxyl propylmethyl cellulose.
22. A method of providing pain relief to a subject in need thereof, the method comprising:
orally administering to the subject an effective amount of the oral dosage form of claim 13 .
23. A method of providing pain relief to a subject in need thereof, the method comprising:
orally administering to the subject an effective amount of the oral formulation of claim 1 .